×
The central stock price target used here is $10 , the arithmetic mean of four verified analyst price targets, rounded from $10.05. Individual targets range widely, from $8 to $13.20 , reflecting substantial disagreement about the company's growth trajectory.
QT Imaging Holdings (QTI) is scheduled to report its third quarter 2026 results on November 10, 2026, after the market close, with a conference call at 4:30 p.m. Eastern Time. Wall Street consensus projects revenue of roughly $10.79 million, more than doubling the $4.19 million reported in the year-ago quarter, alongside a net loss of about $0.09 per share.
The central $5.00 target is the rounded arithmetic mean of three verified analyst price targets ($4.00, $4.00 and $6.25), which average roughly $4.75. With the stock near $1.53, reaching $5.00 would require a gain of about 227%, a very large move by any standard.
Spectral AI (MDAI) is scheduled to report third quarter 2026 results on Tuesday, November 10, 2026, after the Nasdaq market closes, followed by a conference call at 5:00 p.m. Eastern Time. Wall Street consensus calls for earnings per share (EPS) of approximately -$0.14 and revenue of roughly $5.33 million, implying year-over-year revenue growth of about 40%.
The central $11 target is the arithmetic mean of three current analyst price targets — approximately $9, $11, and $13 — giving a low-to-high range of $9 to $13. With shares recently trading near $5.46, reaching $11 would require roughly 101% upside, a very large move that essentially calls for a doubling.
LENSAR reported third quarter 2026 total revenue of $14.1 million , a 1% decline from $14.3 million a year earlier, driven by lower capital system sales against a strong prior-year comparison. Recurring revenue rose 17% year over year to $12.6 million and represented 89% of total revenue , up from 75% a year ago.
The central $4.50 target is the arithmetic mean of the two most recent, attributable analyst price targets: $4.00 (Stifel, August 2026) and $5.00 (Craig-Hallum, March 2026). With shares recently near $1.18 , reaching $4.50 would require a gain of roughly 280% , a very large move.
Total revenue reached $10.2 million in the third quarter of 2026, up 49% from $6.8 million a year earlier. Core revenue grew 27% to $8.2 million , while Strategic Platform License (SPL) program-related revenue contributed roughly $2.0 million.
The central $10 stock price target is the arithmetic mean of five verified analyst price targets (rounded from $10.40). The current price of about $2.80 implies roughly 255% upside to the $10 target—a very large move.
TriSalus Life Sciences (TLSI) reported third quarter 2026 revenue of $12.9 million, up 11.3% year over year and about 13% sequentially, driven by TriNav adoption. Revenue and earnings per share (EPS) both missed consensus, with a net loss of $0.15 per share against expectations for a smaller loss.
The central target of $46 is the arithmetic mean of three verified, current analyst price targets from Lake Street ($47), Freedom Broker ($50), and B. Riley Securities ($40). With the stock near $27.06 , reaching $46 would require a gain of roughly 70% , a very large move by conventional standards.
Electromed, Inc. (NYSE American: ELMD) is scheduled to report its fiscal 2027 first quarter results — for the period ended September 30, 2026 — on November 10, 2026, after the market close. Wall Street consensus points to earnings per share (EPS) of about $0.26 , compared with $0.25 in the same quarter a year earlier.
The central stock price target used here is $13.50 , the arithmetic mean of recent, individually attributable analyst targets rounded to a clean level. The target implies a roughly 17% upside from the latest verified close of $11.51, a substantial but not extreme move.
908 Devices reported third quarter 2026 revenue of $18.95 million, up 35% year over year and a record for the company. Net loss per share from continuing operations narrowed to -$0.11, beating the roughly -$0.16 consensus estimate.
The $19 central target is the arithmetic mean of three verified analyst price targets ($18.80, $19.00, and $20.00), which rounds down from a calculated average of roughly $19.27. With shares near $10.60 after a post-earnings decline, reaching $19 implies a gain of roughly 80% — a very large move.
BrainsWay reported third-quarter 2026 revenue of $18.1 million , up 34% from $13.5 million in the prior-year period. Gross margin expanded to 78% , up from 75% a year earlier, while operating income rose 107% to roughly $2.6 million.
The central reference point is $2.50 , roughly 34% above the most recent closing price near $1.87 — a fallback target grounded in technical levels, not a formal analyst consensus. SS Innovations International, Inc. (SSII) has only one published analyst price target, $7.00 from Lucid Capital Markets, which implies a roughly 274% move and does not amount to a meaningful multi-analyst consensus.
SS Innovations International is expected to report its third-quarter 2026 results in early November, with analysts modeling revenue of roughly $15.1 million. Consensus estimates call for a net loss of about $0.01 per share, roughly in line with the prior quarter's results.
The central target of $17 is the arithmetic mean of seven current analyst price targets, which range from a low of $13 to a high of $19. With shares trading near $14, reaching $17 would require roughly a 22% advance from recent levels.
Lumexa Imaging is scheduled to report its third quarter 2026 results after the market close on Tuesday, November 10, 2026, followed by a conference call at 5:00 p.m. ET. Analyst consensus clusters around $0.20 in adjusted earnings per share (EPS) and roughly $269 million in revenue , a modest step up from the second quarter.